Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Matinas BioPharma Holdings, Inc.
  6. News
  7. Summary
    MTNB   US5768101058

MATINAS BIOPHARMA HOLDINGS, INC.

(MTNB)
  Report
Delayed Nyse  -  05/27 04:00:00 pm EDT
0.7500 USD    0.00%
05/12TRANSCRIPT : Matinas BioPharma Holdings, Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12MATINAS BIOPHARMA HOLDINGS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05/12Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Matinas BioPharma Says Data Monitoring Panel Backs Continuation of Meningitis Trial to Final Patient Cohort

12/16/2021 | 07:36am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
All news about MATINAS BIOPHARMA HOLDINGS, INC.
05/12TRANSCRIPT : Matinas BioPharma Holdings, Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12MATINAS BIOPHARMA HOLDINGS, INC. : Results of Operations and Financial Condition, Regulati..
AQ
05/12Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highligh..
GL
05/12Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highligh..
GL
05/12Note 2 - Liquidity and Plan of Operations
AQ
05/12Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended M..
CI
05/05Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2022 Financial an..
GL
05/03Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference
GL
05/03Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference
AQ
04/13MATINAS BIOPHARMA HOLDINGS, INC. : Regulation FD Disclosure (form 8-K)
AQ
More news
Analyst Recommendations on MATINAS BIOPHARMA HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 0,01 M - -
Net income 2022 -27,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,77x
Yield 2022 -
Capitalization 163 M 163 M -
Capi. / Sales 2022 20 331x
Capi. / Sales 2023 21 401x
Nbr of Employees 31
Free-Float 97,1%
Chart MATINAS BIOPHARMA HOLDINGS, INC.
Duration : Period :
Matinas BioPharma Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,75 $
Average target price 2,75 $
Spread / Average Target 267%
EPS Revisions
Managers and Directors
Jerome D. Jabbour President, Chief Executive Officer & Director
Keith A. Kucinski Chief Financial Officer
Herbert J. Conrad Chairman
Raphael J. Mannino Chief Scientific Officer & Senior Vice President
James J. Ferguson Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MATINAS BIOPHARMA HOLDINGS, INC.-25.74%163
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478